Controversies in the Use of Portal Vein Embolizationvan Gulik T.M.a · van den Esschert J.W.a · de Graaf W.a · van Lienden K.P.b · Busch O.R.C.a · Heger M.a · van Delden O.M.b · Laméris J.S.b · Gouma D.J.a
Departments of aSurgery and bRadiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aims: Portal vein embolization (PVE) has reached worldwide acceptance to increase future remnant liver (FRL) volume before undertaking major liver resection. The aim of this overview is to point out and discuss current controversies in the application of PVE. Methods: Review of literature pertaining to techniques of PVE, complications, tumor proliferation, timing of resection, and hypertrophy response after PVE. Results: Procedure-related complications after PVE include hematoma, hemobilia, overflow of embolization material, and thrombosis of portal vein branch(es) of the non-embolized lobe. Persistence of the embolized, atrophic lobe is usually not harmful. Embolization of the portal branches to segment 4 in addition to embolization of the right portal trunk is controversial and is advised only in selected cases. It remains undecided whether embolization of the portal venous system is more effective in inducing hypertrophy of the FRL than ligation of the portal vein. Accelerated tumor growth after PVE is a major concern and requires consideration of post-PVE chemotherapy. A waiting time of 3 weeks between PVE and liver resection is advised. Post-hepatectomy regeneration is not hampered after preoperative PVE. Conclusion: PVE is a useful preoperative intervention to increase volume and function of the FRL. Further progress awaits clarification of the mechanisms of the hypertrophy response induced by PVE in conjunction with new embolization materials and protective chemotherapy.
© 2009 S. Karger AG, Basel
- Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Long RJ: Preoperative portal vein embolization for major liver resection. A meta-analysis. Ann Surg 2008;247:49–57.
Makuuchi M, Takayasu K, Takuma T: Preoperative transcatheter embolization of the portal venous branch for patients receiving extended lobectomy due to the bile duct carcinoma. J Jpn Surg Assoc 1984;45:1558–1564.
- Makuuchi M, Thai BL, Takayasu K: Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990;107:521–527.
- Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, Sauvanet A: Portal vein embolization prior to right hepatectomy: a prospective clinical trial. Ann Surg 2003;237:208–217.
- Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397–407.
Belghiti J: Arguments for a selective approach of preoperative portal vein embolization before major hepatic resection J Hepatobiliary Pancreat Surg 2004;11:21–24.
Hashimoto T, Makuuchi M: Preoperative portal vein embolization; in Lau WY (ed): Hepatocellular Carcinoma. World Scientific Publishing, 2008, pp 337–358.
- Wilms C, Mueller L, Lenk C, Wittkugel O, Helmke K, Krupski-Berdien G, Rogiers X, Broering DC: Comparative study of portal vein embolization versus portal vein ligation for induction of hypertrophy of the future liver remnant using a mini-pig model. Ann Surg 2008;247:825–834.
- Aussilhou B, Lesurtel M, Sauvanet A, Farges O, Dokmak S, Goasguen N, Sibert A, Vilgrain V, Belghiti J: Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant. J Gastrointest Surg 2008;12:297–303.
- Furrer K, Tian Y, Pfammatter T, Jochum W, El-Badry AM, Graf R, Clavien PA: Selective portal vein embolization and ligation trigger different regenerative responses in the rat liver. Hepatology 2008;47:1615–1623.
- Are C, Iacovitti S, Prete F, Crafa FM: Feasibility of laparoscopic portal vein ligation prior to major hepatectomy. HPB 2008;10:229–233.
- Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN: Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007;94:1386–1394.
De Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM: Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol 2008;Dec 3 [Epub ahead of print].
- Kokudo N, Tada K, Seki M, et al: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001;34:267–272.
- Barbaro B, Di SC, Nuzzo G, et al: Preoperative right portal vein embolization in patients with metastatic liver disease: metastatic liver volumes after RPVE. Acta Radiol 2003;44:98–102.
- Elias D, De Baere T, Roche A, et al: During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999;86:784–788.
- Hemming AW, Reed AI, Howard RJ, et al: Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003;237:686–691.
- Brozek W, Bises G, Girsch T, et al: Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer 2005;41:2347–2354.
- Lautt WW: Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol 1985;249:G549–G556.
- Jozkowicz A, Was H, Dulak J: Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 2007;9:2099–2117.
- Goere D, Farges O, Leporrier J, et al: Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006;10:365–370.
- Covey AM, Brown KT, Jarnagin WR, et al: Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008;247:451–455.
- Vetelainen R, Dinant S, van Vliet A, et al: Portal vein ligation is as effective as sequential portal vein and hepatic artery ligation in inducing contralateral liver hypertrophy in a rat model. J Vasc Interv Radiol 2006;17:1181–1188.
- Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V: Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006;93:1091–1098.
- Nishiyama Y, Yamamoto Y, Hino I, et al: 99mTc galactosyl human serum albumin liver dynamic SPET for pre-operative assessment of hepatectomy in relation to percutaneous transhepatic portal embolization. Nucl Med Commun 2003;24:809–817.
- Nagino M, Ando M, Kamiya J, Uesaka K, Sano T, Nimura Y: Liver regeneration after major hepatectomy for biliary cancer. Br J Surg 2001;88:1084–1091.
- Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ, van Vliet AK, van Gulik TM: Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med 2007;48:685–692.
Van den Esschert JW, De Graaf W, van Lienden KP, Busch ORC, van Delden OM, Gouma DJ, Lameris JS, van Gulik TM: Portal vein embolization before major hepatectomy to increase future remnant liver volume. Neth J Med 2008, in press.
- Yokoyama Y, Nagino M, Nimura Y: Mechanisms of hepatic regeneration following portal vein embolization and partial hepatectomy: a review. World J Surg 2007;31:367–374.
- Lainas P, Boudechiche L, Osorio A, Coulomb A, Weber A, Pariente D, Franco D, Dagher I: Liver regeneration and recanalization time course following reversible portal vein embolization. J Hepatol 2008;49:354–362.
- Lesurtel M, Belghiti J: Temporary portal vein embolization as a starter of liver regeneration. J Hepatol 2008;49:313–315.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.